PANORAMA
Study objective
Generalised Anxiety Disorder (GAD) is a common condition that can cause a persistent and difficult-to-control worry, with a significant impact on daily life. The international PANORAMA study is evaluating whether MM-120 can help reduce anxiety symptoms in people with GAD, and confirm its safety in a controlled clinical setting.
Study design
PANORAMA is a phase III, randomised, double-blind, placebo-controlled clinical trial involving 36 centres in more than five countries. In the first part of the study, participants receive 0mcg, 50mcg, or 100mcg of MM120 in a randomised, double-blind fashion. This is followed by a 40-week extension phase with the opportunity to receive up to four doses of open-label treatment. The study involves several in-person and remote visits for evaluation and follow-up.
Who can participate?
Participation is subject to specific study criteria.
Adults between the ages of 18 and 74 who meet the diagnostic criteria for GAD and have no medical or psychiatric history within the exclusion criteria may be eligible.
For one reason or another, most people who volunteer turn out not to be eligible for a clinical trial. It’s important to be realistic about the chances of inclusion and pursue other sources of help at the same time.
Treatment information
LSD-tartrate is a psychedelic drug, the effects of which can last for several hours. In this study, it is administered exclusively in a dedicated hospital facility and under continuous medical supervision. Its use in GAD is still in the research phase, meaning we are still finding out whether it could be helpful for the condition. Early trials suggest it can indeed be helpful. It is important to remember that psychedelic therapy is not a ‘reset’ for the brain or a ‘quick fix', and it helps to have the right support around you if you do take part in the study.
Study status:
- Open for recruitment.
- Contact: panorama@cntw.nhs.uk
- Study team: Nadia Burman (Tel: 07971 030 758) and Michael Kelly (Tel: 07970 993 197)
- Principal Investigator: Dr. Mourad Wahba – CaPE@cntw.nhs.uk